1-(4-(1-methyl-5-phenyl-1H-benzo[d]imidazol-4-yl)phenyl)cyclobutanamine | 1357158-78-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-(1-methyl-5-phenyl-1H-benzo[d]imidazol-4-yl)phenyl)cyclobutanamine
• 英文别名: 1-[4-(1-Methyl-5-phenylbenzimidazol-4-yl)phenyl]cyclobutan-1-amine
• CAS: 1357158-78-1
• 化学式: C₂₄H₂₃N₃
• 分子量: 353.467
• InChiKey: KQBSFOHZTGMBMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-溴-3-氯-N1-甲苯-1,2-二胺 在 2-双环己基膦-2',6'-二甲氧基联苯 、 四(三苯基膦)钯 、 palladium diacetate 、 sodium carbonate 、 potassium carbonate 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 4.66h， 生成 1-(4-(1-methyl-5-phenyl-1H-benzo[d]imidazol-4-yl)phenyl)cyclobutanamine
  参考文献：
  名称：

  Diverse Heterocyclic Scaffolds as Allosteric Inhibitors of AKT

  摘要：

  Wide-ranging exploration of potential replacements for a quinoline-based inhibitor of activation of AKT kinase led to number of alternative, novel scaffolds with potentially improved potency and physicochemical properties. Examples showed predictable DMPK properties, and one such compound demonstrated pharmacodynamic knockdown of phosphorylation of AKT and downstream biomarkers in vivo and inhibition of tumor growth in a breast cancer xenograft model.

  DOI：

  10.1021/jm201394e

文献信息

• Diverse Heterocyclic Scaffolds as Allosteric Inhibitors of AKT
  作者：Jason G. Kettle、Simon Brown、Claire Crafter、Barry R. Davies、Phillippa Dudley、Gary Fairley、Paul Faulder、Shaun Fillery、Hannah Greenwood、Janet Hawkins、Michael James、Keith Johnson、Clare D. Lane、Martin Pass、Jennifer H. Pink、Helen Plant、Sabina C. Cosulich

  DOI：10.1021/jm201394e

  日期：2012.2.9

  Wide-ranging exploration of potential replacements for a quinoline-based inhibitor of activation of AKT kinase led to number of alternative, novel scaffolds with potentially improved potency and physicochemical properties. Examples showed predictable DMPK properties, and one such compound demonstrated pharmacodynamic knockdown of phosphorylation of AKT and downstream biomarkers in vivo and inhibition of tumor growth in a breast cancer xenograft model.